Dongsung Pharm Cash Flow Conversion Efficiency

Latest as of June 2025: 0.104x

Dongsung Pharm cash flow conversion efficiency. Based on the latest financial reports, Dongsung Pharm (002210) has a cash flow conversion efficiency ratio of 0.104x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.20 Billion ≈ $2.85 Million USD) by net assets (₩40.55 Billion ≈ $27.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Dongsung Pharm (2008–2024)

Cash flow conversion efficiency of Dongsung Pharm from 2008 to 2024. This chart illustrates how Dongsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Dongsung Pharm stock price today for real-time trading data and today's change.

Dongsung Pharm Cash Flow Conversion Ratio Explained

Dongsung Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Dongsung Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Dongsung Pharm ranked by their cash flow conversion efficiency. Also see Dongsung Pharm market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Guler Yatirim Holding AS IS:GLRYH	0.065x
Pantheon International PLC LSE:PIN	-0.007x
Aksu Enerji ve Ticaret AS IS:AKSUE	0.002x
Skycorp Solar Group Limited Ordinary Shares NASDAQ:PN	-0.035x
Smithson Investment Trust PLC LSE:SSON	0.000x
Indivior PLC LSE:INDV	-0.612x
Blossom M&C Co. Ltd KQ:263920	-0.023x
Assura PLC LSE:AGR	0.042x

Annual Cash Flow Conversion Efficiency for Dongsung Pharm (2008–2024)

The table below shows the annual cash flow conversion efficiency of Dongsung Pharm from 2008 to 2024. Review 002210 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩55.18 Billion ≈ $37.39 Million	₩-9.94 Billion ≈ $-6.74 Million	-0.180x	-67.06%
2023-12-31	₩39.80 Billion ≈ $26.97 Million	₩-4.29 Billion ≈ $-2.91 Million	-0.108x	-18.93%
2022-12-31	₩42.81 Billion ≈ $29.01 Million	₩-3.88 Billion ≈ $-2.63 Million	-0.091x	-53.08%
2021-12-31	₩46.44 Billion ≈ $31.47 Million	₩-2.75 Billion ≈ $-1.86 Million	-0.059x	-164.99%
2020-12-31	₩54.95 Billion ≈ $37.24 Million	₩5.01 Billion ≈ $3.40 Million	0.091x	+176.94%
2019-12-31	₩70.10 Billion ≈ $47.50 Million	₩-8.31 Billion ≈ $-5.63 Million	-0.118x	-588.87%
2018-12-31	₩57.48 Billion ≈ $38.96 Million	₩1.39 Billion ≈ $944.20K	0.024x	-13.40%
2017-12-31	₩64.27 Billion ≈ $43.56 Million	₩1.80 Billion ≈ $1.22 Million	0.028x	+146.55%
2016-12-31	₩55.62 Billion ≈ $37.69 Million	₩-3.34 Billion ≈ $-2.27 Million	-0.060x	-36.94%
2011-12-31	₩60.20 Billion ≈ $40.80 Million	₩-2.64 Billion ≈ $-1.79 Million	-0.044x	-170.43%
2010-12-31	₩59.10 Billion ≈ $40.05 Million	₩3.68 Billion ≈ $2.50 Million	0.062x	+184.40%
2009-12-31	₩67.97 Billion ≈ $46.06 Million	₩-5.02 Billion ≈ $-3.40 Million	-0.074x	-1271.65%
2008-12-31	₩67.82 Billion ≈ $45.96 Million	₩-365.26 Million ≈ $-247.53K	-0.005x	--

About Dongsung Pharm

KO:002210 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$18.81 Million

₩27.75 Billion KRW

Market Cap Rank

#25158 Global

#1845 in Korea

Share Price

₩1137.00

Change (1 day)

+4.79%

52-Week Range

₩1085.00 - ₩1688.00

All Time High

₩45800.00